Rheumatoid Arthritis

Discussing the importance of implementing a multidisciplinary team when treating conditions that put patients at a predisposition for comorbidities with Rania Al Asmar, MBBS, of Marshall University.

Janet Pope, MD, professor of medicine at the University of Toronto, discusses whether she believes clinicians will ever transition away from DMARDs and biologics due to the high cost and what the alternatives are for those patients.

Elena Myasoedova, MD, of the Mayo Clinic, discusses the results of a study examining the incidence rates of cardiovascular disease in patients with rheumatoid arthritis across 3 decades.

Rania Al Asmar, MBBS, discusses a study she led and authored that examined prevalence and characteristics of patients with rheumatoid arthritis who later developed coronary artery disease.

Jack Stacy, MSIV, of University of North Dakota, discusses a study he co-authored and presented at CCR West examining the use of low-dose prednisone to induce remission in patients with rheumatoid arthritis.

A cohort assessment of patients treated in a rural academic-based clinic finds just 10% of patients were vaccinated for the disease their RA therapies put them at more risk for.

Postmenopausal women with early rheumatoid arthritis have a metabolic syndrome profile similar to men and should equally be considered high risk for the development of cardiovascular disease, according to Bindee Kuriya M.D, writing in the journal ACR Open Rheumatology.

A new study shows adherence to current ACR guidelines for therapy results in improved disease activity scores.

Methotrexate is the trusted standby in drug regimens to treat rheumatoid arthritis. How much do you know about the current research on methotrexate for rheumatoid arthritis? Take our quiz.

Rheumatoid arthritis patients who achieve low disease activity on tofacitinib in combination with methotrexate, should be able to discontinue methotrexate safely and without significant worsening of disease activity, especially if they are having trouble tolerating it, new research shows.

When considering the evidence, it appears that rather than it being a discrete clinical entity with a unique cause, rheumatoid arthritis (RA) is likely a syndrome that represents a common endpoint for a number of different causative agents.

Patients with rheumatoid arthritis often experience flares when symptoms and functionality worsen. Predicting flares and preventing them is a key area of research in rheumatoid arthrits (RA). In this quiz, test how familiar you are with recent findings in this area.

In patients with rheumatoid arthritis, methotrexate adherence is suboptimal and associated with certain demographics, medication experience, and beliefs about medicines, say researchers writing in ACR Open Rheumatology this month.

In this Q&A, Dr. Roy Fleischmann, the primary investigator for the phase three clinical trial of upadacitinib (Rinvoq, AbbVie), compares the new rheumatoid arthritis treatment to other treatments. 

Triple therapy and methotrexate‐based biologic disease‐modifying antirheumatic drug (DMARD) combinations were superior to methotrexate alone for both American College of Rheumatology (ACR50) response and remission in patients with rheumatoid arthritis, say researchers writing in Arthritis Research & Therapy last month.

In this installment of our monthly rheumatoid arthritis quiz, we focus comorbidities associated with rheumatoid arthritis, adverse drug reactions and the best place to get care in the country. Learn more in this quiz.

Women with rheumatoid arthritis are concerned with pregnancy and parenting issues and require more information from their doctors, say researchers writing in ACR Open Rheumatology this month.

AbbVie announced on Friday that the Food and Drug Administration approved the oral once-daily JAK inhibitor Rinvoq (upadacitinib) for adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

The JAK inhibitor from AbbVie has shown significant benefit for RA patients over 2 weeks of treatment.

The JAK inhibitor could receive consideration as a rheumatoid arthritis therapy in both Europe and the US in the following year.

In today's news roundup from Rheumatology Network, we highlight recent findings from ACR Open Rheumatology that examine infection risk in rheumatoid arthritis patients. Plus, we conduct a Q&A from a presentation made at the Rheumatology Nurses Society on alternative treatments for rheumatology conditions. 

Both TNF inhibitors and non-TNFi biologic DMARDs increase the risk of serious infection in rheumatoid arthritis patients compared to conventional synthetic DMARDs. Despite the risk, the treatments are effective in reducing disease activity, researchers report.

The JAK1 inhibitor filgotinib has been shown to be effective in rheumatoid arthritis patients who failed previous treatment with one or more biologic DMARD.

Modern pharmacologic therapies for rheumatoid arthritisare effective in controlling inflammation and preventing bone erosions however, a multitude of factors are likely to blame for ongoing bone loss in rheumatoid arthritis.